Article Page

Abstract

In the past decade, it was observed that the relationship between the emerging New Molecular Entities and the quantum of R&D investment has not been favorable. There might be numerous reasons but few studies stress the introduction of target based drug discovery approach as one of the factors. Although a number of drugs have been developed with an emphasis on a single protein target, yet identification of valid target is complex. The approach focuses on an in vitro single target, which overlooks the complexity of cell and makes process of validation drug targets uncertain. Thus, it is imperative to search for alternatives rather than looking at success stories of target-based drug discovery. It would be beneficial if the drugs were developed to target multiple components. New approaches like reverse engineering and translational research need to take into account both system and target-based approach. This review evaluates the strengths and limitations of known de novo ligand Identification Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets of a structural ligand-based synthetically accesible pharmacophoric determinant on tau protein-mimic conserved motif peptide chemical elements as an annotated promising therapy in drug discovery approaches and proposes alternative approaches for increasing efficiency against Alzheimer’s disease treatment.

Keywords

drug discovery, drug design, drug targets, repositioning, molecular imaging, Complementary Approaches; Existing; Target Based; Drug Discovery; Identifying; Novel Drug Targets; De novo ligand; Identification;structural; ligand-based; synthetically accesible; pharmacophoric determinant ; tau protein-mimic; conserved motif; peptide chemical; elements; annotated; promising in Alzheimer’s disease;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) De novo ligand Identification Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets of a structural ligand-based synthetically accesible pharmacophoric determinant on tau protein-mimic conserved motif peptide chemical elements as an annotated promising therapy in Alzheimer’s disease.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available